Do you want to read an article? Please log in or register.
Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respirology
Hoyer N, Jessen H, Prior TS, Sand JMB, Leeming DJ, Karsdal MA, Åttingsberg EKA, Vangsgaard GKM, Bendstrup E, Shaker SB
doi: 10.1111/resp.14056
Pulmonary Fibrosis
Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort
Respir Res.
Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, Braybrooke R, Molyneaux PL, North B, Karkera Y, Leeming DJ, Karsdal MA, Nanthakumar CB, Fahy WA, Marshall RP, Jenkins RG, Maher TM
doi: 10.1186/s12931-019-1118-7.
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, Chua F, Wu Z, Wells AU, Renzoni ER, Nicholson AG, Rice A, Lloyd CM, Byrne AJ, Maher TM, Devaraj A, Molyneaux PL
doi: 10.1183/13993003.01519-2019.
Pulmonary Fibrosis
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study
Eur Respir J.
Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C
doi: 10.1183/13993003.
RECOMMENDED
Pulmonary Fibrosis
Lung CT densitometry in idiopathic pulmonary fibrosis (IPF) for the prediction of natural course, severity and mortality
Chest.
Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A
doi: 10.1016/j.chest.
Pulmonary Fibrosis
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Lancet Respir Med.
Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Taha N, D'Amato D, Hosein K, Ranalli T, Sergiacomi G, Zompatori M, Mura M
doi: 10.1186/s12931-020-01371-7.
RECOMMENDED
Pulmonary Fibrosis
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.
doi: 10.1016/j.chest.2019.12.041.